Thursday, April 11, 2019, Anaheim, California, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 3 — Locally Advanced Non-Small Cell Lung Cancer

Location:
Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
Schedule:
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty:
Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Blanca Ledezma, MSN, NP
Nurse Practitioner
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Wendi S Lee, MSN, RN, NP-C
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
5:30 AM – 6:00 AM — Registration and Breakfast Buffet
6:00 AM – 7:30 AM — Educational Program

Cases Presented Will Include Discussion of the Following Topics:

  • Biologic rationale for the evaluation of immune checkpoint inhibitors for Stage III non-small cell lung cancer (NSCLC)
  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III disease
  • Incidence, recognition and management of immune-mediated toxicities associated with durvalumab for unresectable Stage III NSCLC
A detailed agenda will be available in the coming weeks

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding therapeutic recommendations.
  • Appreciate available research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable locally advanced NSCLC.
  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and/or manage these toxicities.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters:
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

There is no registration fee for this event. However, preregistration is highly recommended as seating is limited.

Registration for clinicians in practice

• I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Standby registration for nonclinicians/industry professionals*

For all other professionals, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information. Should seats become available for the program, we will notify you.

Standby registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.